Nivolumab fails to maintain accelerated approval in US for use in liver cancer

The FDA accelerated approval of nivolumab for second line treatment of hepatocellular carcinoma (made on the basis of phase I/II research) has been reversed as the confirmatory phase III CheckMate-459 trial failed to meet its endpoint of improved overall survival vs sorafenib.

Source:

Biospace Inc.